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cohorts were traced for 20 years (4-year Markov cycles) with
55–76 year old patients in order to predict primary and second-
ary CV events. Quarterly titration in year one was set up to a
maximum dose of 20 mg RSV, 80 mg ATV, 80 mg SIM and
40 mg PRA based on TC target, whereas risk was calculated
using average TC : HDL-C ratio of the 1000 simulated patients,
with adjustment for Framingham’s hypothesized over-prediction
of Mexican risk. The economic analysis was done under private
sector perspective with a 5% and 1.5% discount rate for costs
and beneﬁts, respectively. Unitary costs were obtained from
NADRO (local wholesaler). Mexican Institute of Social Security
costs and data from a Delphi Panel were used to estimate
CV diseases’ private costs. Disability-adjusted life years gained
(DALYs) for each treatment regimen were estimated. Results are
shown in natural units, while costs are expressed in US dollars.
Sensitivity analysis included threshold, one-way scenarios and
probabilistic analysis. RESULTS: RSV 10 mg for the 20-year
horizon resulted in less primary and secondary events (197) and
deaths (42), per 1000 patients, more DALYs (14.97) and lower
per-patient treatment costs ($8134.57) than other statins on
equivalent doses. Hence, RSV 10 mg is highly cost-effective with
a cost per DALYs gained of $16,802.15 than comparators.
Sensitivity analysis showed the robustness of results. CONCLU-
SION: RSV is a cost-effective strategy: it yields fewer CV events,
resulting in fewer deaths and signiﬁcant economic saving for
both patients and institutions.
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OBJECTIVE: AVOID (Aliskiren in the Evaluation of Proteinuria
in Diabetes) was a multicentre, randomised, double-blind, six-
month study designed to assess the effect of adding aliskiren, an
oral direct renin inhibitor, to losartan and optimal antihyperten-
sive therapy (excluding ACE inhibitors), on the reduction in
urinary albumin to creatinine ratio (UACR) in patients with
hypertension, type 2 diabetes, and nephropathy. A cost-
effectiveness model was developed aiming to estimate the pro-
gression to end-stage renal disease (ESRD) and to project the
associated costs and clinical outcomes of aliskiren in the UK
setting. METHODS: A previously published Markov model of
diabetic nephropathy and ESRD was adapted to incorporate
treatment effects from AVOID, where aliskiren reduced mean
UACR versus placebo by 20% (p = 0.0009). Transition prob-
abilities from AVOID were used until patients reached UACR
>1,900 mg/g, with probabilities from the Irbesartan in Diabetic
Nephropathy Trial used thereafter. Direct medical costs were
based on UK pharmacy costs and published sources. Annual
discount rates of 3.5% were applied over the 20-year time
horizon. RESULTS: Short-term therapy beneﬁts associated with
aliskiren were projected to increase life expectancy by 0.0983
years (7.9175  0.0434 versus 7.8192  0.0369 years), improve
quality-adjusted life expectancy by 0.0878 quality-adjusted
life years (QALYs) (5.3038  0.0444 versus 5.2160  0.0391
QALYs) and reduce the cumulative incidence of ESRD by 2.51
percent (19.52% versus 22.03%) compared to placebo. An incre-
mental cost-effectiveness ratio of £12,073 per QALY gained was
calculated for aliskiren, which is well below the willingness-to-
pay threshold of the UK of £30,000 per QALY gained. Sensitivity
analysis where the clinical beneﬁt of aliskiren was extended
beyond UACR >1900 mg/g, proved to be a cost saving strategy.
CONCLUSION: Aliskiren would be considered cost-effective in
the UK setting when added to losartan therapy due to the addi-
tional renal protection provided and a reduced incidence of
ESRD.
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OBJECTIVE: To investigate the cost-effectiveness of a diagnostic
imaging strategy starting with magnetic resonance angiography
(MRA) enhanced with a blood pool agent versus strategies start-
ing with either MRA enhanced with conventional extracellular
agents or standard-DSA in severe peripheral arterial occlusive
disease (PAOD) in Canada. METHODS: A microsimulation
model focusing on “diagnostic conﬁdence” instead of “diagnos-
tic accuracy”, built by Kienbaum et al. (submitted for publica-
tion) for the European perspective was adapted to compare a
strategy with initial MRA with Gadofosveset to strategies with
either initial MRA with conventional extracellular contrast
media (standard-MRA) or a standard digital subtraction angiog-
raphy (standard-DSA) in the work-up of severe PAOD (critical
limb ischemia) in the Canadian setting. The model allows evalu-
ating aggregated mean costs per initial diagnostic modality as
well as incremental costs per quality-adjusted life year (QALY)
gained. Both efﬁcacy and utility data were derived from the
European analysis. Cost data were calculated from the payer
perspective and estimated by the ‘Program for the Assessment
of Technology in Health’ (PATH) at McMaster University.
RESULTS: The model simulation predicts an equivalent utility
score for all alternatives considered. From the payer perspective,
the mean overall cost of the Gadofosveset-MRA strategy amount
to $7814. In contrast, aggregated costs with either standard-
MRA or -DSA reach $8637 and $9842, respectively. Thus, an
imaging strategy with initial Gadofosveset-MRA is less costly
than strategies initially using standard-MRA or -DSA. With
regard to cost-effectiveness the additional costs per QALY gained
by standard-MRA versus Gadofosveset-MRA amount to about
$117,000 and about $178,000 for standard-DSA. The model
was robust regarding probabilistic variations of all parameters.
CONCLUSION: From the payer perspective in Canada, an
imaging strategy starting with Gadofosveset-MRA represents a
cost-effective option for the diagnostic work-up of severe PAOD
(critical limb ischemia) compared to strategies with either
standard-MRA or -DSA.
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OBJECTIVE: Some new antidiabetic drugs such as insulin
glargine, insulin detemir, exenatide, and rosiglitazone have been
widely used in the clinical practice. Very few pharmacoeconomics
studies on diabetes medications are focused on these drugs. To
compare and contrast the cost-effectiveness of the various diabe-
tes medications, we conducted the systematic review of drug-
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